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ABSTRACT
Introduction: The phase III MPACT trial in
patients with metastatic pancreatic cancer
(MPC) demonstrated superior efficacy of
nab-paclitaxel (nab-P) plus gemcitabine (Gem)
compared with Gem monotherapy, including
the primary endpoint of overall survival (OS;
median 8.7 vs. 6.6 months; hazard ratio [HR]
0.72; P\0.001). A significant treatment
difference favoring nab-P ? Gem over Gem was
observed for OS in patients treated in North
America. The majority of patients were from the
US (88%) with only 12% from Canada.
Healthcare systems and treatment patterns are
different between the 2 countries, and there is
limited published information on outcomes of
Canadian patients treated with first-line
nab-P ? Gem. This analysis evaluated efficacy
and safety outcomes in Canadian patients in
the MPACT trial.
Methods: Treatment-naive patients with MPC
(N = 861) received either nab-P 125 mg/
m2 ? Gem 1000 mg/m2 on days 1, 8, and 15
every 4 weeks or Gem 1000 mg/m2 weekly for
the first 7 of 8 weeks (cycle 1) and then on days
1, 8, and 15 every 4 weeks (cycle C2).
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Results: The MPACT trial enrolled 63 patients
in Canada. Baseline characteristics were well
balanced and comparable with those of the
intent-to-treat population. Both OS (median
11.9 vs. 7.1 months; HR 0.76; P = 0.373) and
progression-free survival (median 7.2 vs.
5.2 months; HR 0.65; P = 0.224) were
numerically longer and overall response rate
(27% vs. 17%; P = 0.312) was numerically
higher with nab-P ? Gem vs. Gem. The most
common grade C3 adverse events with
nab-P ? Gem vs. Gem were neutropenia (22%
vs. 10%), fatigue (34% vs. 33%), and
neuropathy (25% vs. 0%).
Conclusion: This subanalysis confirmed that
nab-P ? Gem is an efficacious treatment option
and has a manageable safety profile in patients
with MPC treated in Canada.
Trial registration: ClinicalTrials.gov identifier,
NCT00844649.
Funding: Celgene Corporation, Summit, NJ,
USA.
Keywords: Canada; Gemcitabine; Metastatic
pancreatic cancer; MPACT; nab-Paclitaxel;
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INTRODUCTION
Pancreatic cancer (PC) is the fourth leading
cause of cancer-related mortality in Canada, the
US, and Europe [1–3]. Estimates suggested that
in 2015, 4800 Canadians were diagnosed with
PC and 4600 died from the disease [1]. The
5-year relative survival ratio, which compares
survival of patients with cancer to those
without cancer, is 8% among Canadian
patients with PC [1]. The observed 5-year
survival rate for patients with PC is also 8%, a
statistic that has not improved in the last
40 years [4]. Risk factors for the development
of PC include smoking and obesity in addition
to several well-established genetic mutations
[5].
Surgery is the only potentially curative
treatment for PC; however, surgical resection
is an option in only 17% vs. 19% of Canadian
PC cases [6]. Patients who are not eligible for
surgery may be treated with systemic cancer
therapy. For many years, gemcitabine (Gem)
has been a standard treatment for metastatic PC
(MPC) in Canada [4]. In addition, erlotinib is
approved in Canada for the treatment of MPC,
and the combination regimen of leucovorin,
5-fluorouracil (5-FU), irinotecan, and
oxaliplatin (FOLFIRINOX) has been approved
in some provinces [4]. The most recent regimen
to gain approval for the treatment of MPC is
nab-paclitaxel (nab-P) plus Gem [4, 7]. Since
receiving this approval, nab-P ? Gem has been
evaluated by the pan-Canadian Oncology Drug
Review [8] and has been deemed reimbursable
by most but not all Canadian provinces [4].
Health Canada approved nab-P ? Gem for
the treatment of MPC based on the results
of the phase III MPACT trial (N = 861;
ClinicalTrials.gov identifier, NCT00844649),
which compared nab-P ? Gem vs. Gem alone
[7]. In the MPACT trial, nab-P ? Gem
demonstrated superior efficacy in all trial
endpoints, including the primary endpoint of
overall survival (OS; median 8.5 vs. 6.7 months;
hazard ratio [HR] 0.72; P\0.001) [9]. An
updated analysis revealed an even greater
difference in median OS: 8.7 vs. 6.6 months
(HR 0.72; P\0.001) [10]. The combination of
nab-P ? Gem vs. Gem alone also demonstrated
a longer progression-free survival (PFS; median
5.5 vs. 3.7 months; HR 0.69; P\0.001) and
higher overall response rate (ORR) by both
independent (23% vs. 7%; P\0.001) and
investigator (29% vs. 8%; P\0.001) review [9].
Grade C3 adverse events in the MPACT trial
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were effectively managed by dose reductions
and treatment delays.
MPACT was a global trial that enrolled
patients at 151 community and academic sites
in North America (63%), Eastern Europe (15%),
Australia (14%), and Western Europe (9%) [9].
Because cancer mortality rates vary among
countries worldwide [11] (likely a reflection of
differences in healthcare systems), clinical trials
in oncology routinely stratify patient
randomization by region. Geographic region
was a stratification factor in the MPACT trial, as
were performance status and presence or
absence of liver metastases [9]. A significant
treatment difference was observed for OS within
the North American patient population, which
consisted of patients primarily from the US
(88%) and a small subset from Canada (12%).
Additionally, a stepwise multivariate analysis
revealed a lower risk of death for patients in
North America, regardless of treatment [12].
Healthcare systems and treatment patterns are
different between the US and Canada, and
limited published information is available on
the outcomes of Canadian patients treated with
first-line nab-P ? Gem. To understand how
nab-P ? Gem compared with Gem alone in
Canadian patients, a subanalysis of the
MPACT trial was undertaken to compare
efficacy, safety, and treatment exposure in the
subgroup of patients treated in Canada.
METHODS
The MPACT trial was approved by the
independent ethics committee at each
participating institution and was conducted in
accordance with the International Conference
on Harmonisation E6 requirements for Good
Clinical Practice [9]. All procedures followed
were in accordance with the ethical standards
of the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
Patients
Study design and patient characteristics for the
phase III MPACT trial have been described
previously [9]. Briefly, adults (C18 years of age)
with a Karnofsky performance status (KPS) C70,
no prior chemotherapy received for metastatic
disease, and histologically or cytologically
confirmed MPC as assessed by Response
Evaluation Criteria In Solid Tumors (RECIST;
version 1.0) [13] were included in this analysis.
Patients were permitted to have received 5-FU
or Gem as a radiation sensitizer in the adjuvant
setting, provided that treatment was received
C6 months prior to randomization. Adequate
hematologic, hepatic, and renal function was
also required.
Study Design
Patients were randomized 1:1 to receive (1)
intravenous nab-P 125 mg/m2 followed by
intravenous Gem 1000 mg/m2 on days 1, 8,
15, 29, 36, and 43 of an 8-week cycle (cycle 1),
then on days 1, 8, and 15 every 4 weeks for each
subsequent cycle or (2) Gem 1000 mg/m2
weekly for the first 7 weeks of an 8-week cycle
(cycle 1), then for the first 3 weeks of a 4-week
cycle (cycle C2). Patients were stratified
according to KPS, presence of liver metastases,
and geographic region. Patients were treated
until either disease progression or
unacceptable toxicity. Tumor response was
evaluated every 8 weeks using spiral computed
tomography or magnetic resonance imaging. At
baseline and every 8 weeks thereafter, serial
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measurements of carbohydrate antigen 19-9
(CA 19-9) levels were obtained. The primary
endpoint was OS, and secondary endpoints
were PFS and ORR, as assessed by independent
radiological review according to RECIST version
1.0. Also examined was OS as a function of
specific decreases in CA 19-9 levels (20% and
60%). Safety was graded by the National Cancer
Institute Common Terminology Criteria for
Adverse Events, version 3.0 [14], and
summarized according to the Medical
Dictionary for Regulatory Activities, version
15.0 [15].
Statistical Analyses
Efficacy analyses were performed on all
randomized patients in the Canadian cohort.
The Kaplan–Meier method was used to
determine OS, and statistical significance was
assessed with a log-rank test. A stratified Cox
proportional hazards model was used to
determine the associated HR and two-sided
95% confidence intervals (CIs). For patients
who were lost to follow-up, survival data were
censored at the last date that they were known
to be alive. The original cutoff for OS analysis
was September 17, 2012. A nonstratified
log-rank test was PFS between the treatment
arms, and the HR and two-sided 95% CIs were
estimated by a Cox proportional hazards model.
Differences in ORR were assessed by v2 test.
RESULTS
Baseline Characteristics
A total of 63 patients (33 receiving nab-P ? Gem
and 30 receiving Gem alone) were randomized
for treatment at 7 Canadian centers (average
number of patients per center was 4.7 for
nab-P ? Gem and 4.3 for Gem alone). In
general, baseline characteristics were well
balanced between the 2 treatment arms in the
Canadian cohort and were similar to those of
the intent-to-treat (ITT) population from the
MPACT trial; however, some differences were
noted (Table 1) [9]. The Canadian cohort
included a greater percentage of male patients,
patients with C3 metastatic sites, and patients
with a biliary stent compared with the ITT
population. Fewer patients in the Canadian
cohort had a KPS of 100 or previous Whipple
procedure than in the ITT population. In the
Canadian cohort, there was a greater percentage
of patients whose primary tumor was located in
the head of the pancreas in the nab-P ? Gem
arm compared with the Gem-alone arm.
Efficacy
Overall Survival in the Canadian Population
The OS data in the Canadian population were
based on 47 deaths (75% of the population),
including 24 in the nab-P ? Gem arm (73%) and
23 in the Gem-alone arm (77%). In the
Canadian cohort, OS was numerically longer
with nab-P ? Gem vs. Gem alone (median 11.9
vs. 7.1 months; HR 0.76; 95% CI 0.41–1.40;
P = 0.373; Fig. 1). Kaplan–Meier estimates of OS
at 24 months following randomization were
15% for nab-P ? Gem and 9% for Gem alone.
Progression-Free Survival
For the PFS analysis by independent radiological
review, 38 patients in the Canadian cohort
(60%) either had progressive disease or had
died, including 23 (70%) in the nab-P ? Gem
arm and 15 (50%) in the Gem-alone arm. In the
Canadian cohort, PFS was numerically longer in
patients treated with nab-P ? Gem vs. Gem
alone (median 7.2 vs. 5.2 months; HR 0.65;
95% CI 0.32–1.31; P = 0.224; Table 2).
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Table 1 Baseline characteristics
Variable Patients in Canada ITT population [9]
(N5 861)nab-P 1 Gem (n5 33) Gem (n5 30)
Age, median (range), years 61.0 (34–77) 61.5 (49–72) 63.0 (27–88)
Sex, n (%)
Female 12 (36) 9 (30) 359 (42)
Male 21 (64) 21 (70) 502 (58)
KPS, n (%)
100 2 (6) 3 (10) 138 (16)a
90 18 (55) 14 (47) 378 (44)a
80 9 (27) 12 (40) 277 (32)a
70 4 (12) 1 (3) 63 (7)a
60 0 0 2 (\1)a
Number of metastatic sites, n (%)
1 4 (12) 1 (3) 54 (6)
2 11 (33) 11 (37) 408 (47)
C3 18 (55) 18 (60) 399 (46)
Sites of metastases, n (%)
Liver 27 (82) 25 (83) 725 (84)
Lung 14 (42) 18 (60) 337 (39)
Peritoneum 2 (6) 1 (3) 29 (3)
Pancreatic tumor location, n (%)
Head 18 (55) 9 (30) 371 (43)
Body 11 (33) 11 (37) 268 (31)
Tail 4 (12) 10 (33) 215 (25)
Unknown 0 0 7 (1)
CA 19-9, n (%)
Normal 3 (9) 3 (10) 116 (15)b
[ULN and\59 9 ULN 11 (33) 11 (37) 242 (32)b
C59 9 ULN 16 (48) 11 (37) 392 (52)b
Unknown 3 (9) 5 (17) 111 (13)c
Biliary stent, n (%) 11 (33) 8 (27) 62 (7)
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Overall Response Rate
The independently assessed ORR in the
Canadian cohort was numerically higher in
patients treated with nab-P ? Gem vs. Gem
alone (27% vs. 17%; response rate ratio, 1.64;
95% CI 0.62–4.34; P = 0.312; Table 2). No
Canadian patient in either treatment arm
achieved a complete response. The disease
control rate (partial response ? stable disease
[for C16 weeks]) was also numerically higher in
Canadian patients treated with nab-P ? Gem
than in patients treated with Gem alone (58%
vs. 37%; response rate ratio, 1.57; P = 0.097).
Evaluation of CA 19-9 Levels
Patients in the Canadian cohort were evaluated
for CA 19-9 levels at baseline and every 8 weeks.
Assessment of OS in relation to CA 19-9
decrease (both 20% and 60%) was based on
the 39 patients who had a measurement at
baseline and C1 time point after baseline. In a
pooled analysis of these 39 patients (which
included both treatment groups), OS was
significantly longer in Canadian patients who
had a C20% CA 19-9 decrease from baseline to
nadir compared with those who had a \20%
decrease (median 14.5 vs. 7.8 months; HR 0.28;
Table 1 continued
Variable Patients in Canada ITT population [9]
(N5 861)nab-P 1 Gem (n5 33) Gem (n5 30)
Previous Whipple procedure, n (%) 3 (9) 2 (7) 148 (17)
CA 19-9 carbohydrate antigen 19-9, Gem gemcitabine, ITT intent-to-treat, KPS Karnofsky performance status,
nab-P nab-paclitaxel, ULN upper limit of normal
a Total evaluable patients = 858
b Total evaluable patients = 750
c This value was not reported in Reference [9]
Fig. 1 Overall survival in Canadian patients. Kaplan–
Meier curve of overall survival for patients in Canada
treated with either nab-paclitaxel ? gemcitabine or
gemcitabine alone. P value was generated from a log-rank
test. CI conﬁdence interval, Gem gemcitabine, HR hazard
ratio, nab-P nab-paclitaxel
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95% CI 0.12–0.68; P = 0.003; Table S1).
Similarly, OS was significantly longer in
patients with a C60% CA 19-9 decrease from
baseline to nadir than in those with a \60%
decrease (median 15.7 vs. 9.2 months; HR 0.40;
95% CI 0.17–0.91; P = 0.025). The maximum
absolute percentage reductions in CA 19-9 from
baseline (median) were 87.3% and 78.2% for
patients in the nab-P ? Gem and Gem-alone
arms, respectively.
Treatment Exposure and Secondary Therapy
Use
In general, treatment duration was slightly
longer, but cumulative doses were similar in
the Canadian subgroup compared with the ITT
population. The median treatment duration
was 4.1 months (range 0.3–20.7) in patients
treated with nab-P ? Gem and 3.1 months
(range 0.6–16.6) in patients treated with Gem
alone (Table 3). In the nab-P ? Gem arm, 50% of
patients had C1 nab-P dose reduction and 38%
had C1 Gem dose reduction. Forty percent of
patients in the Gem-alone arm had C1 dose
reduction. In the nab-P ? Gem arm, the median
percentage of per-protocol doses given was
75.0% and 81.2% for nab-P and Gem,
respectively. The median percentage of
per-protocol dose given in the Gem-alone arm
was 85.0%. For patients treated with
nab-P ? Gem, the median nab-P dose intensity
was 68.4 mg/m2/week, and the median Gem
dose intensity was 627.8 mg/m2/week. The
median dose intensity for Gem alone was
667.3 mg/m2/week.
Fewer patients in the nab-P ? Gem arm
received a subsequent therapy than in the
Gem-alone arm (30% vs. 43%; Table 4).
Table 2 PFS and ORR by independent radiological review in patients in Canada and the ITT population
Variable Patients in Canada ITT population [9]
nab-P 1 Gem (n5 33) Gem (n 5 30) nab-P 1 Gem (n5 431) Gem (n5 430)
PFS
Median PFS, months 7.2 5.2 5.5 3.7
HR (95% CI) 0.65 (0.32–1.31) 0.69 (0.58–0.82)
P value 0.224 \0.001
ORR
ORR, n (%) 9 (27) 5 (17) 99 (23) 31 (7)
RRR (95% CI) 1.64 (0.62–4.34) 3.19 (2.18–4.66)
P value 0.312 \0.001
Complete response, n (%) 0 0 1 (\1) 0
Partial response, n (%) 9 (27) 5 (17) 98 (23) 31 (7)
Stable disease, n (%) 10 (30) 8 (27) 118 (27) 122 (28)
Progressive disease, n (%) 4 (12) 6 (20) 86 (20) 110 (26)
Not evaluable, n (%)a 10 (30) 11 (37) 128 (30) 167 (39)
CI conﬁdence interval, Gem gemcitabine HR hazard ratio, ITT intent-to-treat, nab-P nab-paclitaxel, ORR overall response
rate, PFS progression-free survival, RRR response rate ratio
a Includes patients who did not have a postbaseline assessment
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In both treatment arms, 5-FU- or
capecitabine-based regimens were the most
commonly used secondary therapies.
Safety
The most common grade C3 nonhematologic
adverse events were fatigue and peripheral
neuropathy, which occurred in 34% and 25%
of patients treated with nab-P ? Gem and
33% and 0% of patients treated with Gem
alone, respectively (Table 5). Neutropenia was
the most common grade C3 hematologic
adverse event in both treatment arms (22%
for nab-P ? Gem and 10% for Gem alone).
The rates of grade C3 anemia,
thrombocytopenia, and leukopenia were
similar between the 2 treatment arms. Grade
C3 vomiting was slightly more common in
the Gem-alone arm vs. nab-P ? Gem arm
(13% vs. 6%).
Table 3 Treatment exposure in patients in Canada and the treated population
Treatment exposure and dose
modiﬁcation
Patients in Canada All treated patients [9]
nab-P 1 Gem
(n 5 32)
Gem (n5 30) nab-P 1 Gem
(n5 421)
Gem (n5 402)
Treatment duration, median (range),
months
4.1 (0.3–20.7) 3.1 (0.6–16.6) 3.9 (0.1–21.9) 2.8 (0.1–21.5)
No. of treatment cycles administered,
median (range)
4.0 (1–20) 2.5 (1–17) 3.0 (1–23) 2.0 (1–23)
Cumulative nab-P dose, median, mg/m2 1412.5 – 1425.0 –
Cumulative Gem dose, median, mg/m2 12,000.0 9800.0 11,400.0a 9000.0
Average nab-P dose intensity, median
(range), mg/m2/week
68.4 (15.6–95.5) – 74.13 (15.6–96.0) –










Percentage of protocol nab-P dose, median
(range)
75.0 (16.7–100.0) – 80.6 (16.7–100.0) –






Patients with C1 nab-P dose reduction,
n (%)
16 (50) – 172 (41) –
Patients with C1 Gem dose reduction,
n (%)
12 (38) 12 (40) 198 (47) 132 (33)
Patients with C1 nab-P dose delay/not
given, n (%)
25 (78) – 300 (71) –
Patients with C1 Gem dose delay/not given,
n (%)
23 (72) 20 (67) 295 (70) 230 (57)
Gem Gemcitabine, nab-P nab-paclitaxel
a Total evaluable patients in the population = 420
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DISCUSSION
This subanalysis of the MPACT trial evaluated
the efficacy and safety outcomes with
nab-P ? Gem vs. Gem alone in patients treated
in Canada. The results in the Canadian cohort
were consistent with those in the ITT
population, in which nab-P ? Gem was
associated with improved OS, ORR, and PFS
compared with Gem alone [9]. A survival
difference of nearly 5 months was observed
between the nab-P ? Gem and Gem-alone
arms in the Canadian subpopulation (median
11.9 vs. 7.1 months); however, this difference
Table 4 Subsequent therapy in patients in Canada and the ITT population









Patients with any subsequent therapy, n (%) 10 (30) 13 (43) 162 (38) 179 (42)
5-FU/Cape-based 9 (27) 11 (37) 131 (30) 155 (36)
FOLFIRINOX (modiﬁed/unmodiﬁed) 2 (6) 3 (10) 19 (4) 25 (6)
Other 2 (6) 3 (10) 43 (10) 50 (12)
Erlotinib-based 1 (3) 0 13 (3) 11 (3)
5-FU 5-ﬂuorouracil; Cape capecitabine; FOLFIRINOX leucovorin, 5-FU, irinotecan, oxaliplatin; Gem gemcitabine; ITT
intent-to-treat; nab-P nab-paclitaxel
Table 5 Adverse events in patients in Canada and the treated population









Patients with at least 1 grade C3 AE, n (%) 30 (94) 22 (73) NR NR
Hematologic AEs, n (%)
Neutropenia 7 (22) 3 (10) 153 (38)a 103 (27)b
Anemia 3 (9) 2 (7) 53 (13)a 48 (12)b
Thrombocytopenia 2 (6) 1 (3) 52 (13)a 36 (9)b
Leukopenia 1 (3) 0 124 (31)a 63 (16)b
Nonhematologic AEs, n (%)
Fatigue 11 (34) 10 (33) 70 (17) 27 (7)
Peripheral neuropathyc 8 (25) 0 70 (17) 3 (1)
Vomiting 2 (6) 4 (13) NR NR
AE adverse event, Gem gemcitabine, nab-Pnab-paclitaxel, NR not reported
a Total evaluable patients in the population = 405
b Total evaluable patients in the population = 388
c Grouped AE term
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did not reach statistical significance. In
addition, the 7% of patients treated in Canada
had numerically longer OS and PFS and a higher
ORR than patients globally in the ITT
population, especially those receiving
nab-P ? Gem, although the outcomes could
not be compared statistically given that the
Canadian patients were a small subset and such
a comparison was not planned in the trial
protocol.
In general, treatment exposure and
secondary therapy use were similar in the
Canadian and ITT populations [9]; however,
fewer Canadian patients treated with
nab-P ? Gem received a subsequent therapy
than ITT patients treated with nab-P ? Gem.
Patients in the Canadian cohort had a lower
incidence of hematologic adverse events than
those in the ITT population, but Canadian
patients had higher incidences of fatigue (both
treatment arms) and peripheral neuropathy
(nab-P ? Gem only) than ITT patients.
An examination of baseline characteristics
and treatment exposure did not reveal the
reasons for the efficacy observed in the
Canadian population. In fact, the Canadian
cohort had higher rates of certain baseline
characteristics that might be expected to be
associated with worse efficacy, including the
percentages of patients who were male, had C3
sites of metastasis, or had a KPS \100 [11,
16–19]. Furthermore, as described herein, the
treatment exposure in the Canadian cohort was
similar to that in the ITT population, and the
rates of secondary therapy use were similar or
slightly lower than in the ITT population.
Conversely, there was a higher rate of patients
per treatment center in the Canadian cohort (63
patients/7 centers = 9 patients/center) vs. the
ITT population (861 patients/151 centers = 5.7
patients/center), suggesting the possibility that
study physicians in the Canadian cohort could
have become more familiar with the
per-protocol treatments. The potential effect of
this familiarity on efficacy and tolerability is
difficult to quantify.
In the MPACT trial, there was a lower risk of
death for patients in North America, regardless
of treatment. Whether unique features of the
Canadian healthcare system might have
influenced efficacy outcomes among patients
in the MPACT trial is an interesting question.
Canadian citizens have access to universal
healthcare through the single-payer system;
thus, all patients receive the same level of
care. Universal healthcare may have allowed
Canadian patients as a whole to receive more
uniform access to medical visits, supportive care
medications, and second-line therapies. The
universal healthcare system also provides
educational awareness programs and special
care for those in need, including the elderly.
The impact of these differences on treatment
effectiveness at this point is speculative.
This subanalysis was subject to a number of
limitations. This was an unplanned, post hoc
analysis; no consideration in the study design
was given to allowing for statistical comparisons
within the cohort. In addition, this analysis
included only 63 patients; this small sample
size was likely the factor that prevented
numerous treatment arm comparisons from
reaching statistical significance. Finally, some
differences were apparent between the
treatment arms in the Canadian cohort of
patients, including the higher percentage with
tumors in the head of the pancreas in the
nab-P ? Gem arm vs. the Gem-alone arm at
baseline and the higher percentage in the
Gem-alone arm who received secondary
therapies. These limitations must be kept in
mind when interpreting the results of the study.
Health Canada has approved nab-P ? Gem
and FOLFIRINOX for the treatment of patients
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with MPC based on the phase III MPACT and
PRODIGE trials (ClinicalTrials.gov identifier,
NCT00112658), respectively, in which
nab-P ? Gem and FOLFIRINOX demonstrated
superior efficacy vs. Gem alone [4, 9, 20].
However, there is little clinical evidence to
guide treatment selection between these
regimens. Direct comparisons across the trials
are not appropriate given differences in patient
populations. A recent retrospective analysis
investigated the likelihood of meeting
eligibility criteria for the MPACT and
PRODIGE trials and possible associations with
efficacy among patients with MPC who were
treated with Gem at British Columbia regional
cancer centers between January 2000 and
December 2011 [21]. The analysis found that
45% and 25% of the analyzed cohort would
have been eligible to receive nab-P ? Gem and
FOLFIRINOX, respectively. Performance status
and elevated bilirubin level were the most
frequent reasons for ineligibility regardless of
whether MPACT or PRODIGE criteria were
applied. Furthermore, the study suggested that
simply meeting eligibility criteria had a
dramatic impact on efficacy outcomes: even
though all patients were treated with Gem,
those who met the more stringent criteria of the
PRODIGE trial had a longer median OS than
those who met the more inclusive criteria of the
MPACT trial (8.6 vs. 6.7 months). These data
suggest a substantial correlation between
eligibility criteria and efficacy, illustrating the
importance of randomized trials for comparing
treatments and avoiding cross-trial
comparisons.
CONCLUSIONS
This subanalysis confirmed that nab-P ? Gem is
an efficacious treatment option for Canadian
patients with MPC and has a manageable safety
profile. The consistency of the findings in the
overall treatment population lends support to
their overall implications, despite certain
limitations, such as the small sample size.
Additional data on the efficacy and safety of
nab-P ? Gem in Canadian patients are likely to
become increasingly available as physicians
continue to use the regimen to treat their
patients with MPC.
ACKNOWLEDGMENTS
Sponsorship for this study and article
processing charges was funded by Celgene
Corporation, Summit, NJ, United States. All
named authors meet the International
Committee of Medical Journal Editors (ICMJE)
criteria for authorship of this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval to the
version to be published. Editorial assistance in
the preparation of this manuscript was provided
by Aaron Runkle, PhD, of MediTech Media.
Support for this assistance was funded by
Celgene Corporation. The authors were fully
responsible for all content and editorial
decisions of this manuscript.
Disclosures. Scot Dowden has participated
in advisory boards as a speaker for Amgen,
Bayer, Celgene, Lilly, and Roche. Hagen
Kennecke has received honoraria and research
support from Amgen and honoraria from
Celgene and Novartis. Helen Liu is an
employee and stockholder of Celgene. Robert
El-Maraghi has participated in advisory boards
as a speaker and has received honoraria from
Celgene and Lilly, and has participated in
advisory boards and received travel support
and honoraria from Roche. Alfredo Romano is
an employee and stockholder of Celgene.
Adv Ther (2016) 33:747–759 757
Mustapha Tehfe has participated in advisory
boards for Celgene, Lilly, Ipsen, Merck, and
Novartis and has been a speaker for Celgene,
Lilly, Amgen, and Novartis. Bernard Lesperance,
Felix Couture, and Richard Letourneau declare
that they have no conflicts of interest.
Compliance with Ethics Guidelines. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. CanadianCancer Society.Canadian cancer statistics.
2015. Available at: http://www.cancer.ca/*/media/
cancer.ca/CW/cancer%20information/cancer%20101
/Canadian%20cancer%20statistics/Canadian-Cancer-
Statistics-2015-EN.pdf. Accessed Nov 9, 2015.
2. American Cancer Society. Cancer facts and
figures. 2015. Available at: http://www.cancer.org/
acs/groups/content/@editorial/documents/document/
acspc-044552.pdf. Accessed Nov 9, 2015.
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J,
et al. Cancer incidence and mortality patterns in
Europe: estimates for 40 countries in 2012. Eur J
Cancer. 2013;49:1374–403.
4. Pancreatic Cancer Canada. Know the facts and
statistics. Available at: http://www.pancreaticcancer
canada.ca/site/PageServer?pagename=facingpan
creaticcancer_facts. Accessed Nov 9, 2015.
5. Chiorean EG, Coveler AL. Pancreatic cancer:
optimizing treatment options, new, and emerging
targeted therapies. Drug Des Devel Ther.
2015;9:3529–45.
6. Hurton S, MacDonald F, Porter G, Walsh M,
Molinari M. The current state of pancreatic cancer
in Canada: incidence, mortality, and surgical
therapy. Pancreas. 2014;43:879–85.
7. Cancer Care Ontario. nab-Paclitaxel drug
monograph. 2015.
8. Pan-Canadian Oncology Drug Review.
Pan-Canadian oncology drug review final
economic guidance report: nab-paclitaxel
(Abraxane) for pancreatic cancer. Available at:
https://www.cadth.ca/sites/default/files/pcodr/pcodr-
abraxane-mpc-fn-egr.pdf. Accessed Nov 9, 2015.
9. Von Hoff DD, Ervin T, Arena FP, et al. Increased
survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 2013;369:
1691–703.
10. Goldstein D, El-Maraghi RH, Hammel P, et al.
Nab-paclitaxel plus gemcitabine for metastatic
pancreatic cancer: long-term survival from a phase
III trial. J Natl Cancer Inst. 2015;107:dju413.
11. World Health Organization. GLOBOCAN 2012:
estimated cancer incidence, mortality and
prevalence worldwide in 2012. Available at: http://
globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
Accessed Sept 17, 2015.
12. Tabernero J, Chiorean EG, Infante JR, et al.
Prognostic factors of survival in a randomized
phase III trial (MPACT) of weekly nab-paclitaxel
plus gemcitabine versus gemcitabine alone in
patients with metastatic pancreatic cancer.
Oncologist. 2015;20:143–50.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New
guidelines to evaluate the response to treatment in
solid tumors. European Organization for Research
and Treatment of Cancer, National Cancer Institute
of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 2000;92:205–16.
14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0:
development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin
Radiat Oncol. 2003;13:176–81.
15. MedDRA Maintenance and Support Services
Organization. Introductory Guide to MedDRA
Version 15.0. Chantily: MedDRA Maintenance
and Support Services Organization; 2012. http://
758 Adv Ther (2016) 33:747–759
www.meddra.org/sites/default/files/guidance/file/
intguide_15_0_english.pdf. Accessed Mar 24,
2016.
16. Kou T, Kanai M, Yamamoto M, et al. Prognostic
model for survival based on readily available
pretreatment factors in patients with advanced
pancreatic cancer receiving palliative
chemotherapy. Int J Clin Oncol. 2016;21:118–25.
17. Blank PR, Szucs TD. Pancreas cancer: influence of
gender and other demographic and clinical
parameters on survival [abstract 200]. J Clin
Oncol. 2014;32(suppl 3).
18. Xue P, Zhu L, Wan Z, et al. A prognostic index
model to predict the clinical outcomes for
advanced pancreatic cancer patients following
palliative chemotherapy. J Cancer Res Clin Oncol.
2015;141:1653–60.
19. Bolm L, Janssen S, Kasmann L, et al. Predicting
survival after irradiation of metastases from
pancreatic cancer. Anticancer Res. 2015;35:4105–8.
20. Conroy T, Desseigne F, Ychou M, et al.
FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 2011;364:1817–25.
21. Peixoto RD, Ho M, Renouf DJ, et al. Eligibility of
metastatic pancreatic cancer patients for first-line
palliative intent nab-paclitaxel plus gemcitabine
versus FOLFIRINOX. Am J Clin Oncol. 2015. [Epub
ahead of print].
Adv Ther (2016) 33:747–759 759
